

Abstract

Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a local anaesthetic such as lidocaine, polidocanol or prilocaine are provided, which are useful in particular in the treatment of dermatological diseases such as atopic, contact or seborrhoeic dermatitis, psoriasis, acne, rosacea, post-peel, pruritus, skin burning, or itching; and associated pain.